photo: find / ben phillips find specimen bank
TRANSCRIPT
FIND SPECIMEN BANK Q1 2019 – Q4 2020 Activity Report & Updates
Photo: FIND / Ben Phillips
Q1 2019 - Q4 2020 Activity Report & Updates
FIND Specimen Bank
FIND manages a high-quality biorepository with over 480,000 well-characterized samples from more than 14,500 participants enrolled in over 25 sites across the globe. This unique resource is able to provide specimens to support product development efforts across four of FIND’s focus areas: TB (60% of samples), malaria (28%), non-severe acute fever management (6%) and hepatitis C (6%). Sample types include sputum, urine, plasma, serum, PAXgene, cell free DNA urine and cell free DNA blood. All specimens are collected at qualified clinics, under a protocol approved by an Institutional Review Board and with informed consent from patients.
About FIB
Since July 2020, FIND has been supporting a network of strategically positioned biobanks − FIND Integrated Biobanks (FIB) − across Africa, South East Asia, South America and Europe. Working together with our partners, the aim of this network is to build capacity for inclusive, ethical, and efficient biobanking services − improving access to high-quality samples.
FIND’s network of integrated biobanks enables for sample collection and distribution to be mobilized locally in response to user need. All ethical, legal and regulatory frameworks are overseen by FIND, who provides the resources, training and support needed to standardize services and makes sure quality benchmarks are met. This helps to ensure the availability of high-quality samples with requests managed through a single point of contact that streamlines distribution and harmonizes resources ready for deployment.
Photo: FIND/Katie G.Nelson
COVID-19 biobank activitiesFIND is conducting a prospective study to collect and store bacteriologically and clinically well-characterized reference materials of adult COVID-19 suspects in Peru. Up to December 2020, 253 participants were enrolled at UPCH (Peru). 72 participants were SARS-Cov-2 positive and 148 were SARS-Cov-2 negative (confirmed with PCR results at baseline and week 1 visits). A total of 33 participants were classified as inconclusive/invalid and did not have their results entered in the database. Of these, 15,451 aliquots were collected at baseline visits, 3,059 at week 1, 410 at week 2, 1,875 at week 4, 61 at week 5, 1,446 at week 8, and 63 at week 9. All samples are stored and available for distribution.
*
53 51 52
Distribution of material requests
2019
Number of MRFs** submitted*
Number of MRFs approved*
Number of MRFs distributed*
*Some MRFs were approved the previous year but aliquots were distributed the following year.
**request forms
Distribution of samples
Number of aliquots approved*
Number of aliquots distributed*
3
9,1998,94110,56812,570
Number of aliquots approved*
Number of aliquots distributed*
68 54 54
20202019
2020
Distribution of specimens
Between Q1 2019 – Q4 2020, the FIND specimen bank distributed 19,767 aliquots, fulfilling 106 requests. See the graphs below for details.
Number of MRFs submitted*
Number of MRFs approved*
Number of MRFs distributed*
Distribution of specimens per type
2020
2019
Serum: 3,295
Plasma: 2,450
Blood: 2,217
Urine: 968
Sputum: 624
Culture isolate:
605
Saliva: 339
PBMC: 70
Urine: 3,010
Plasma: 1,909
Blood: 923
Serum: 1,122
Sputum: 1,560
Culture isolate:
560
Saliva: 115
Legend
Urine
Plasma
Saliva
Blood
Sputum
PBMC
Culture isolate
Serum
4
Specimen inventory
The FIND repository currently holds 481,644 aliquots from collection sites in Cambodia, Cameroon, Côte d’Ivoire, Georgia, Greece, Moldova, Nigeria, Peru, Senegal, South Africa, Tanzania, the United Kingdom, Uganda, Ukraine and Viet Nam. FIND also manages the WHO-TDR TB collection, which includes 28,347 aliquots from Spain, The Gambia, El Salvador, Peru, South Africa, Tanzania, Uganda, Viet Nam, Canada, Bangladesh, Brazil, Colombia , and Kenya.
5
Viet NamGreece
Georgia
Ukraine
Cameroon
Côte d'Ivoire
South Africa
Peru
United Kingdom
7905
1650
931
2083
8831
184510991016
1930
Senegal
Cambodia
Tanzania
Uganda
Nigeria
Moldova
HCV: 4,976 specimens Malaria: 11,400 specimens TB: 10,936 specimens
Incoming specimens 2020
Legend
HCVMalariaTBPre-existing inventory
Culture isolate: 5242
Saliva:22,558
Blood:100,879
Urine: 5,311
Malaria: 133,990 specimens TB: 288,226 specimens
Culture isolate:45,461
DNA:9,939Plasma:46,693
SalivaBlood: 7,375Serum:47,178
Sputum:75,356
Urine:56,174
Saliva: 50
Plasma:10,212
Blood:11,243
Serum: 6,749
Urine:2,868
Fever: 31,072 specimens HCV: 28,356 specimens
Plasma:25,471
Blo
od: 2
,132
Seru
m: 7
53
Specimen inventory
6
Revenue
As FIND is a non-profit organization, requestors are asked to cover all shipping costs. We also charge a small handling fee per sample (US$ 50–200 depending on the sample type and characterization) towards operational activities. FIND received 334,919 US$ from material requesters between 2014 and September 2020.
Strains/DNA isolates and matching specimens
Specimens from MDR/XDR-TB patients were collected from globally representative sites in South America, South East Asia, Africa and Eastern Europe. These include sputum, plasma, serum and PAXgene tubes. Strains are characterized by whole genome sequencing and phenotypic testing against first- and second-line drugs and the minimum inhibitory concentration. Over 1,000 strain isolates are currently available.
Number and type of specimen Number of MDR/XDR participants
10,532 Sputum aliquots
7,311 Serum aliquots
8,785 Plasma aliquots
391 Paxgene aliquots
5,729 DNA aliquots
17,506 culture isolates
1,227 participants
1,271 participants
1,271 participants
391 participants
753 participants
754 participants
7
Quality control
To improve quality and ensure high standards, FIND implemented quality control and quality assurance processes for blood, sputum, and urine samples. Including recording critical data about the collection, conducting additional baseline testing, and applying stringent monitoring of storage conditions and processing times. For instance, baseline testing of urine samples with dipsticks is now allowing documentation of the physical characteristics of the sample and presence of proteins, glucose, ketones, haemoglobin, bilirubin, urobilinogen, acetone, nitrite, and leucocytes.
Information on materials distributed per requester
Photo: FIND/Katie G.Nelson
2019
Fever
HCV
Malaria
9
0 50 100 150 200 250 300
Molbio Diagnostics Pvt. Ltd. Karnataka
NBCL, B.V.
Chembio Diagnostics Systems, Inc.
Qorvo
Mologic Ltd.
DCN Diagnostics 167
135
97
87
70
10
0 250 500 750 1000 1250 1500 1750
Meso Scale Diagnostics
MICROSYNTH
Inflammatix
NMI 1650
512
511
184
Requesters
0 50 100 150 200 250 300 350 400 450 500 550 600
Mologic Ltd.
Global Good Funf (GGF)
Lab. Malaria (309) LID
Access Bio, Inc
PATH
MICROSYNTH [570]193188189
[394]244150
125
72
60
60
Requesters
Requesters
Urine PlasmaSalivaWhole blood
Legend
Aliquots distributed
Aliquots distributed
Aliquots distributed
TB
10
0 150 300 450 600 750 900 1050 1200 1350 1500
NRL Australia
PHRI
NHLS
ITRC
NIRT
QUIDEL
GenEndeavor
Gigabiomol
Hain Lifescience GmbH
PATH
San Raffaele
Research Center Borstel
David Wright Laboratory
Biomerieux
DCN Diagnostics
Proteogenix
ZeptoMetrix Inc.
Stony Brook University
Biotem
Unima
NJH
QMRL
Pace Diagnostics
Cepheid AB
NMI
Meso Scale Diagnostics
Wyss Institute of Harvard University 1300 [1400]100
480
455
440
420
407
400
270
100 100
50 505050
[200]
[200]
200
70 50 [120]
110
100
100100
93
80844 [52]
3010 [40]
50
2020 [40]
3830
20
10
4
Requesters
Urine Plasma
SalivaWhole blood
Sputum
PBMCCulture isolate
Serum
Legend
Aliquots distributed
2020
Fever
Malaria
11
Requesters
Requesters
Urine PlasmaSalivaWhole blood
Legend
0 50 100 150 200 250 300
San Raffaele
LSTM
A. Mayor Laboratory
NMI
Cepheid USA
DCN Diagnostics
Duke University
20
90
100
100 200
20
20
45
[300]
0 50 100 150 200 250 300
LSHTM
Bionote, INC.
Arista Biologicals Inc
Shenzen Bioeasy Biotechnology Co., Ltd
INTEC PRODUCTS, Inc
MICROSYNTH
Purdue University
A. Mayor Laboratory
Wyss Institute of Harvard University
80
25
81 80
8
60
6
35 25 40
30
250
[100]
[241]
82
Aliquots distributed
Aliquots distributed
TB
12
0 200 400 600 800 1000 1200 1400 1600 1800 2000
Cepheid AB
InBios International Inc.
UCSF/Gladstone
CSU
Clemedi AG
Cepheid USA
KEI
Meso Scale Diagnostics
Scanogen Inc.
Washington UniversitySchool of Medicine
RIT/JATA
PATH
LSI Medience Corporation
Wyss Institute of Harvard University
Stellenbosch University
LUMC
DCN Diagnostics
FIND
San Raffaele
Biotem 1799 46 [1845]
150 333
300
480
100175
800
320
560
[483]
[275]
480
175
6
80
60
60
30
83
6060
139
2020
8181 [162]
[120]
[40]
167
Urine Plasma
SalivaWhole blood
Sputum
PBMCCulture isolate
Serum
Legend
Requesters
HCV
14 [1231]
0 200 400 600 800 1000 1200 1400 1600 1800 2000
Molbio DiagnosticsPvt. Ltd. Karnataka
DCN Diagnostics 1217
76 5 [81]
Requesters
Aliquots distributed
Aliquots distributed
Campus Biotech,Chemin de Mines 9,
1202 Geneva - SwitzerlandT: +41 (0)22 710 05 90 – F: +41 (0)22 710 05 99
www.finddx.org